ACETAMINOPHEN
| Brand name | ACETAMINOPHEN |
|---|---|
| Active ingredient | ACETAMINOPHEN |
| Strength | 650MG/65ML (10MG/ML) |
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Modality | Small molecule |
| FDA approval | May 2025 |
| Marketing status | RX |
| Code | Expires |
|---|---|
| PC | January 2026 |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.